Recent news on Coagulation Factor Viia

Minnesota Thermal Science Awarded Special Forces Contract for ...  -  May 1, 2007
Emediawire (press release),...its recently designed specialized thermal container that will be used by US Special Forces to transport emergency dosages of "Coagulation Factor VIIa.

Food and Drug Administration Public Hearing of the Conduct of ...  -  Mar 30, 2007
AEM (subscription)Five years ago, we began using recombinant human coagulation factor VIIa as a rescue therapy for patients with intractable hemorrhage, and I started to work

Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the ...  -  Feb 27, 2007
PipelineReview.com (press release),NovoSeven® (recombinant human coagulation factor VIIa) has been developed by Novo Nordisk. It is licensed for the treatment of bleeding episodes and for the

Prophylactic Factor VIIa Improves Quality of Life for Hemophiliacs ...  -  Dec 11, 2006
DG NewsORLANDO, FL -- December 11, 2006 -- Once daily administration of recombinant human coagulation factor VIIa as secondary prophylaxis against joint bleeding

Decreased Bleeding Frequency With Secondary Prophylactic Use Of ...  -  Dec 13, 2006
Medical News Today (press release),Data presented at the 48th Annual Meeting of the American Society of Hematology (ASH) from a study testing the use of NovoSeven® Coagulation Factor VIIa

FDA Approves Supplemental Use of NovoSeven(R) Coagulation Factor ...  Oct 17, 2006
17, 2006 -- The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven(R) Coagulation Factor VIIa (Recombinant), making ... -DG News NovoSeven(R) Becomes First and Only Recombinant Therapy for ...  Oct 17, 2006
...~ FDA Approves Supplemental Use of NovoSeven(R) Coagulation Factor VIIa (Recombinant) for Treatment of Acquired Hemophilia ~ PRINCETON, NJ, Oct. ... -PR Newswire (press release), Market Report -- In Play (NVO)  Oct 17, 2006
Novo-Nordisk A/S announces the FDA has approved a new indication for NovoSeven Coagulation Factor VIIa Co announces the FDA has approved a new indication for ... -MSN Money Market Report -- In Play (NVO)  Oct 27, 2006
...by 16% in the first nine months of 2006: sales of insulin analogs increased by 52%; sales of NovoSeven Coagulation Factor VIIa (Recombinant) increased by 13 ... -MSN Money FDA Approves Nuvelo's (NUVO) Recombinant Therapy to Treat Rare ...  Oct 17, 2006
Nuvelo Inc. (NUVO) said the FDA has approved a new indication for NovoSeven Coagulation Factor VIIa (Recombinant), making it the first and only recombinant ... -StreetInsider.com (subscription), NovoSeven(R) Becomes First and Only Recombinant Therapy for ...  Oct 17, 2006
PRNewswire/ -- The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven® Coagulation Factor VIIa (Recombinant), making ... -Yahoo! News (press release) Novo Nordisk Announces Financial Statement for the First Nine ...  Oct 27, 2006
...by 16% in the first nine months of 2006 - Sales of insulin analogs increased by 52% - Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by ... -MSN Money NovoSeven Approved for Additional Indication  Oct 20, 2006
The FDA has approved Novo Nordisk’s SNDA for NovoSeven (coagulation factor VIIa [recombinant]) for the treatment of acquired hemophilia. ... -Facts and Comparisons, Prophylactic Factor VIIa Improves Quality of Life for Hemophiliacs ...  -  Dec 11, 2006
DG NewsORLANDO, FL -- December 11, 2006 -- Once daily administration of recombinant human coagulation factor VIIa as secondary prophylaxis against joint bleeding ...

Novo Nordisk Reports 20% Increase In First Half Reported Sales ...  Aug 2, 2006
...last year. Specifically, sales of insulin analogs increased by 59% and NovoSeven Coagulation Factor VIIa improved by 19%. Sales ... -Trading Markets

Novo Nordisk Increased Sales by 20% in the First Six Months  Aug 2, 2006
...by 20% in the first six months of 2006 -- Sales of insulin analogs increased by 59% -- Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by ... -Finanzen.net

Recombinant Factor VIIa and Thromboembolic Events  Jul 4, 2006
To the Editor: Dr O’Connell and colleagues 1 reviewed thromboembolic complications of recombinant human coagulation factor VIIa (rFVIIa) as reported to the ... -Journal of American Medical Association (subscription)



Novo Nordisk withdraws NovoSeven marketing extension application  Apr 7, 2006
NovoSeven (Human recombinant coagulation Factor VIIa (rFVIIa)) was first authorized in the European Union in February 1996 and is currently indicated for the ... - Pharmaceutical Business Review

Novo Nordisk Withdraw Their Application To Extend The Marketing ...  Apr 6, 2006
...withdraw the application for an extension of the marketing authorisation for the medicinal product NovoSeven (Human recombinant coagulation Factor VIIa (rFVIIa ... - Medical News Today

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional